<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Moleculin Biotech Inc — News on 6ix</title>
<link>https://6ix.com/company/moleculin-biotech-inc</link>
<description>Latest news and press releases for Moleculin Biotech Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 23 Apr 2026 12:25:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/moleculin-biotech-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835961878dffbe2df1046ce.webp</url>
<title>Moleculin Biotech Inc</title>
<link>https://6ix.com/company/moleculin-biotech-inc</link>
</image>
<item>
<title>Moleculin’s Annamycin Extends Survival by More Than 60% in Metastatic Pancreatic Cancer Preclinical Models - Data Presented at AACR 2026</title>
<link>https://6ix.com/company/moleculin-biotech-inc/news/moleculins-annamycin-extends-survival-by-more-than-60percent-in-metastatic-pancreatic-cancer-preclinical-models-data-presented-at-aacr-2026</link>
<guid isPermaLink="true">https://6ix.com/company/moleculin-biotech-inc/news/moleculins-annamycin-extends-survival-by-more-than-60percent-in-metastatic-pancreatic-cancer-preclinical-models-data-presented-at-aacr-2026</guid>
<pubDate>Thu, 23 Apr 2026 12:25:00 GMT</pubDate>
<description>Non-cardiotoxic anthracycline demonstrates activity where traditional chemotherapies have historically failed, supporting potential expansion of Annamycin into a major unmet-need indication Significant tumor volume reduction across multiple PDAC models, including orthotopic human and syngeneic systems (p<0.001) Significantly higher tumor and pancreatic tissue accumulation than doxorubicin (p<0.0001), providing a mechanistic basis for Annamycin’s activity where traditional anthracyclines have his</description>
</item>
<item>
<title>Moleculin Announces Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting</title>
<link>https://6ix.com/company/moleculin-biotech-inc/news/moleculin-announces-abstract-accepted-for-poster-presentation-at-the-2026-asco-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/moleculin-biotech-inc/news/moleculin-announces-abstract-accepted-for-poster-presentation-at-the-2026-asco-annual-meeting</guid>
<pubDate>Tue, 21 Apr 2026 12:36:00 GMT</pubDate>
<description>HOUSTON, April 21, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that an abstract highlighting data on its lead drug candidate, annamycin, has been accepted for poster presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 – June 2, 2026, in Chicago, Illinois. The abstract, titled “Cardiac safety of L-annamycin at high cumulative anthracycline exposure: Pooled analysis,” will be</description>
</item>
<item>
<title>Moleculin Releases Next CEO Corner Segment Highlighting Annamycin’s Non-Cardiotoxic Profile</title>
<link>https://6ix.com/company/moleculin-biotech-inc/news/moleculin-releases-next-ceo-corner-segment-highlighting-annamycins-non-cardiotoxic-profile</link>
<guid isPermaLink="true">https://6ix.com/company/moleculin-biotech-inc/news/moleculin-releases-next-ceo-corner-segment-highlighting-annamycins-non-cardiotoxic-profile</guid>
<pubDate>Tue, 07 Apr 2026 04:00:00 GMT</pubDate>
<description>Access the Moleculin CEO Corner here HOUSTON, April 07, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today</description>
</item>
<item>
<title>Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout</title>
<link>https://6ix.com/company/moleculin-biotech-inc/news/moleculin-hits-45-subject-enrollment-milestone-triggering-final-countdown-to-mid-2026-miracle-trial-data-readout</link>
<guid isPermaLink="true">https://6ix.com/company/moleculin-biotech-inc/news/moleculin-hits-45-subject-enrollment-milestone-triggering-final-countdown-to-mid-2026-miracle-trial-data-readout</guid>
<pubDate>Mon, 23 Mar 2026 04:00:00 GMT</pubDate>
<description>First Interim Unblinding of Pivotal AML Trial Now Imminent — Potentially the Most Important Data Moment in Company HistoryEarly Blinded Results Show 40%</description>
</item>
<item>
<title>Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026</title>
<link>https://6ix.com/company/moleculin-biotech-inc/news/moleculin-reports-full-year-2025-financial-results-and-confirms-highly-anticipated-45-patient-interim-data-unblinding-in-pivotal-miracle-trial-on-track-for-mid-2026</link>
<guid isPermaLink="true">https://6ix.com/company/moleculin-biotech-inc/news/moleculin-reports-full-year-2025-financial-results-and-confirms-highly-anticipated-45-patient-interim-data-unblinding-in-pivotal-miracle-trial-on-track-for-mid-2026</guid>
<pubDate>Thu, 19 Mar 2026 04:00:00 GMT</pubDate>
<description>Miracle Trial Preliminary Blinded CRc Rate of 40% in First 30 Patients Suggests Encouraging Early Results in Relapsed/Refractory AML HOUSTON, March 19, 2026</description>
</item>
<item>
<title>Moleculin to Present at 38th Annual ROTH Conference</title>
<link>https://6ix.com/company/moleculin-biotech-inc/news/moleculin-to-present-at-38th-annual-roth-conference</link>
<guid isPermaLink="true">https://6ix.com/company/moleculin-biotech-inc/news/moleculin-to-present-at-38th-annual-roth-conference</guid>
<pubDate>Tue, 17 Mar 2026 13:05:00 GMT</pubDate>
<description>– Management to participate in fireside chat presentation with Jonathan Aschoff, Senior Research Analyst at ROTH Capital Partners HOUSTON, March 17, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that it will participate in a fireside chat at the 38th Annual ROTH Conference being held March 22-24, 2026 in Dana Point, CA. Details of the fireside chat presentation are as follows: Date and Time: Tuesday, March 24, 2026 at 12:00-12:25</description>
</item>
<item>
<title>Moleculin Releases Next CEO Corner Segment Highlighting MIRACLE Study</title>
<link>https://6ix.com/company/moleculin-biotech-inc/news/moleculin-releases-next-ceo-corner-segment-highlighting-miracle-study-15</link>
<guid isPermaLink="true">https://6ix.com/company/moleculin-biotech-inc/news/moleculin-releases-next-ceo-corner-segment-highlighting-miracle-study-15</guid>
<pubDate>Wed, 11 Mar 2026 04:00:00 GMT</pubDate>
<description>Access the Moleculin CEO Corner here HOUSTON, March 11, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today</description>
</item>
<item>
<title>Moleculin Announces Exercise of Warrants for $8.3 Million Gross Proceeds</title>
<link>https://6ix.com/company/moleculin-biotech-inc/news/moleculin-announces-exercise-of-warrants-for-dollar83-million-gross-proceeds</link>
<guid isPermaLink="true">https://6ix.com/company/moleculin-biotech-inc/news/moleculin-announces-exercise-of-warrants-for-dollar83-million-gross-proceeds</guid>
<pubDate>Thu, 19 Feb 2026 13:39:00 GMT</pubDate>
<description>HOUSTON, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced it has entered into agreements with certain holders of its existing warrants for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,122,652 shares of common stock of the Company at an exercise price of $3.90 per share. The issuance or resale of the shares of common stock issuable upon exercise of the outstanding warrants has be</description>
</item>
<item>
<title>Moleculin MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=30)</title>
<link>https://6ix.com/company/moleculin-biotech-inc/news/moleculin-miracle-trial-delivers-40-132000354</link>
<guid isPermaLink="true">https://6ix.com/company/moleculin-biotech-inc/news/moleculin-miracle-trial-delivers-40-132000354</guid>
<pubDate>Wed, 18 Feb 2026 13:20:00 GMT</pubDate>
<description>Preliminary blinded CR rate showed 67% improvement over historical cytarabine response Roughly 35% of the subjects treated to date represent ventoclax regimen failuresFirst 45 subjects treated on track for Q1 2026 milestone with unblinding thereafter; treated 35 subjects to date with another 11 identified Continued absence of cardiotoxicity and high efficacy expected to position Annamycin as a “significant advancement” in AML treatment HOUSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech</description>
</item>
<item>
<title>Moleculin Announces Notice of Allowance for Japanese Patent Covering Annamycin</title>
<link>https://6ix.com/company/moleculin-biotech-inc/news/moleculin-announces-notice-of-allowance-for-japanese-patent-covering-annamycin</link>
<guid isPermaLink="true">https://6ix.com/company/moleculin-biotech-inc/news/moleculin-announces-notice-of-allowance-for-japanese-patent-covering-annamycin</guid>
<pubDate>Tue, 17 Feb 2026 13:35:00 GMT</pubDate>
<description>HOUSTON, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that the Japan Patent Office (JPO) has issued a notice of allowance for Patent Application No. 2021-577862 titled, “METHOD OF RECONSTITUTING LIPOSOMAL ANNAMYCIN.” A patent from the application is expected to be issued in the coming months. The allowed claims cover proprietary methods for reconstituting and preparing liposomal Annamycin from a preliposomal lyophilizat</description>
</item>
<item>
<title>Moleculin Launches CEO Corner Platform to Share Strategic Insights</title>
<link>https://6ix.com/company/moleculin-biotech-inc/news/moleculin-launches-ceo-corner-platform-133200258</link>
<guid isPermaLink="true">https://6ix.com/company/moleculin-biotech-inc/news/moleculin-launches-ceo-corner-platform-133200258</guid>
<pubDate>Fri, 13 Feb 2026 13:32:00 GMT</pubDate>
<description>CEO Corner segments intended to provide added perspective to press releases, clinical trial developments and pipeline progress Provides interested parties with the ability to connect with the Company by submitting questions and topics for future videos Access the Moleculin CEO Corner here HOUSTON, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced the launch of its CEO Corner, a new platform featuring Walter Klemp, Chief Exec</description>
</item>
<item>
<title>Moleculin to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial</title>
<link>https://6ix.com/company/moleculin-biotech-inc/news/moleculin-participate-corporate-connect-webinar-141500705</link>
<guid isPermaLink="true">https://6ix.com/company/moleculin-biotech-inc/news/moleculin-participate-corporate-connect-webinar-141500705</guid>
<pubDate>Thu, 05 Feb 2026 14:15:00 GMT</pubDate>
<description>– Live video webcast on Wednesday, February 11th at 1:20 PM EST HOUSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that it will participate in the Corporate Connect Webinar Series hosted by Webull Financial being held virtually February 10-11, 2026. Details of the presentation are as follows: Date and Time: Wednesday, February 11, 2026 at 1:20 PM ESTPresenter: Walter Klemp, Founder, President, CEO and Chairman of Mol</description>
</item>
<item>
<title>Moleculin Reports Independent Assessment Confirms No Cardiotoxicity of Annamycin in 90 Subjects</title>
<link>https://6ix.com/company/moleculin-biotech-inc/news/moleculin-reports-independent-assessment-confirms-135500602</link>
<guid isPermaLink="true">https://6ix.com/company/moleculin-biotech-inc/news/moleculin-reports-independent-assessment-confirms-135500602</guid>
<pubDate>Tue, 13 Jan 2026 13:55:00 GMT</pubDate>
<description>– Annamycin consistently demonstrates no evidence of cardiotoxicity across five clinical trials – This next-generation anthracycline demonstrates safety and promising early activity in treating multiple oncology indications HOUSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), announced it has received a new independent assessment for the absence of cardiotoxicity in subjects treated with Annamycin, bringing the total number of Annamyc</description>
</item>
<item>
<title>Moleculin Reports Independent Assessment Confirms No Cardiotoxicity of Annamycin in 90 Subjects </title>
<link>https://6ix.com/company/moleculin-biotech-inc/news/moleculin-reports-independent-assessment-confirms-no-cardiotoxicity-of-annamycin-in-90-subjects</link>
<guid isPermaLink="true">https://6ix.com/company/moleculin-biotech-inc/news/moleculin-reports-independent-assessment-confirms-no-cardiotoxicity-of-annamycin-in-90-subjects</guid>
<pubDate>Tue, 13 Jan 2026 05:00:00 GMT</pubDate>
<description>– Annamycin consistently demonstrates no evidence of cardiotoxicity across five clinical trials – This next-generation anthracycline demonstrates safety and</description>
</item>
<item>
<title>Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs</title>
<link>https://6ix.com/company/moleculin-biotech-inc/news/moleculin-accelerates-outlook-2026-first-133600051</link>
<guid isPermaLink="true">https://6ix.com/company/moleculin-biotech-inc/news/moleculin-accelerates-outlook-2026-first-133600051</guid>
<pubDate>Mon, 12 Jan 2026 13:36:00 GMT</pubDate>
<description>– First MIRACLE trial unblinding expected Q1 2026; Global trial now spans nine countries – Investigator-Initiated (IIT) funded pancreatic and brain cancer trials HOUSTON, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today provided a business outlook and outlined expected upcoming milestones for its next generation n</description>
</item>
<item>
<title>Moleculin Announces Positive Results from Phase 1 Clinical Trial Evaluating WP1066 for the Treatment of Pediatric Recurrent Malignant Brain Tumors</title>
<link>https://6ix.com/company/moleculin-biotech-inc/news/moleculin-announces-positive-results-from-phase-1-clinical-trial-evaluating-wp1066-for-the-treatment-of-pediatric-recurrent-malignant-brain-tumors</link>
<guid isPermaLink="true">https://6ix.com/company/moleculin-biotech-inc/news/moleculin-announces-positive-results-from-phase-1-clinical-trial-evaluating-wp1066-for-the-treatment-of-pediatric-recurrent-malignant-brain-tumors</guid>
<pubDate>Wed, 17 Dec 2025 13:31:00 GMT</pubDate>
<description>Emory University physician-sponsored clinical trial conducted at the Aflac Cancer and Blood Disorders Center at Children’s Healthcare of AtlantaResults demonstrated WP1066 induces anti-tumor immune responses and were recently published in the Journal of Clinical Investigation Insight WP1066 found to be safe and effective, warranting a Phase 2 trial HOUSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced positive results f</description>
</item>
<item>
<title>Moleculin Announces Exercise of Warrants for $6.8 Million Gross Proceeds</title>
<link>https://6ix.com/company/moleculin-biotech-inc/news/moleculin-announces-exercise-of-warrants-for-dollar68-million-gross-proceeds</link>
<guid isPermaLink="true">https://6ix.com/company/moleculin-biotech-inc/news/moleculin-announces-exercise-of-warrants-for-dollar68-million-gross-proceeds</guid>
<pubDate>Wed, 10 Dec 2025 13:30:00 GMT</pubDate>
<description>HOUSTON, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced it has entered into agreements with certain holders of its existing warrants for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 727,969 shares of common stock of the Company originally issued in February 2</description>
</item>
<item>
<title>Moleculin Announces Completion of Treatment for the 45 Patients in Pivotal “MIRACLE” Phase 3 AML Trial on Pace for Q1 2026</title>
<link>https://6ix.com/company/moleculin-biotech-inc/news/moleculin-announces-completion-of-treatment-for-the-45-patients-in-pivotal-miracle-phase-3-aml-trial-on-pace-for-q1-2026</link>
<guid isPermaLink="true">https://6ix.com/company/moleculin-biotech-inc/news/moleculin-announces-completion-of-treatment-for-the-45-patients-in-pivotal-miracle-phase-3-aml-trial-on-pace-for-q1-2026</guid>
<pubDate>Tue, 09 Dec 2025 13:07:00 GMT</pubDate>
<description>Continues to drive enrollment with increase to 78% now consentedBlinded response activity tracking within expected range Consented subjects now across seven countries supporting the expansion of the MIRACLE trial HOUSTON, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today provided an update on enrollment from its November report with an increase to 78% of the target number of subjects for the first planned interim unblinding of data ha</description>
</item>
<item>
<title>Moleculin Announces New Annamycin Collaboration in Brain Tumors</title>
<link>https://6ix.com/company/moleculin-biotech-inc/news/moleculin-announces-new-annamycin-collaboration-in-brain-tumors</link>
<guid isPermaLink="true">https://6ix.com/company/moleculin-biotech-inc/news/moleculin-announces-new-annamycin-collaboration-in-brain-tumors</guid>
<pubDate>Mon, 08 Dec 2025 13:21:00 GMT</pubDate>
<description>Investigator-Initiated Preclinical studies at CIC biomaGUNE aimed at combatting Glioblastoma Multiforme Research will evaluate effects of intra-arterial delivery of Annamycin HOUSTON, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viral infections, today announced it has entered into a research and material transfer agreement</description>
</item>
<item>
<title>Moleculin to Participate in the Virtual Investor Closing Bell Series</title>
<link>https://6ix.com/company/moleculin-biotech-inc/news/moleculin-to-participate-in-the-virtual-investor-closing-bell-series</link>
<guid isPermaLink="true">https://6ix.com/company/moleculin-biotech-inc/news/moleculin-to-participate-in-the-virtual-investor-closing-bell-series</guid>
<pubDate>Wed, 26 Nov 2025 14:15:00 GMT</pubDate>
<description>Live video webcast with Walter Klemp, Chairman and Chief Executive Officer, on Tuesday, December 2nd at 4:00 PM ET HOUSTON, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that Walter Klemp, Chairman and Chief Executive Officer of Moleculin will participate in the Virtual Investor Closing Bell Series on</description>
</item>
</channel>
</rss>